Down syndrome, antioxidant balance and the “gene dosage effect” hypothesis

Oxidative Stress and Neurodegenerative Disorders

Volumn , Issue , 2007, Pages 219-235

  de Haan, J B ^a,b   Crack, P J ^b,c   Pritchard, M A ^b   Kola, I ^d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882466803     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044452809-4/50150-2     Document Type: Chapter

References (115)

1. D Patterson (1987) The causes of Down syndrome. Sci Am 257 42-49.
2. D Patterson (1987) The causes of Down syndrome. Sci Am 257 60.
3. KE Wisniewski, AJ Dalton, C McLachlan, GY Wen and HM Wisniewski (1985) Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 35 957-961.
4. DM Mann and MM Esiri (1989) The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 89 169-179.
5. J Busciglio and BA Yankner (1995) Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378 776-779.
6. H Rehder (1981) Pathology of trisomy 21 — with particular reference to persistent common atrioventricular canal of the heart. Hum Genet. Suppl 2 57-73.
7. S Chadushu, E Yefenof, A Becker, J Shapira and G Chaushu (2002) Severe impairment of secretory Ig production in parotid saliva of Down Syndrome individuals. J Dent Res 81 308-312.
8. CT Fong and GM Brodeur (1987) Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet 28 55-76.
9. CF Tam and RL Walford (1980) Alterations in cyclic nucleotides and cyclase-specific activities in T lymphocytes of aging normal humans and patients with Down's syndrome. J Immunol 125 1665-1670.
10. MA Pritchard and I Kola (1999) The “gene dosage effect” hypothesis versus the “amplified developmental instability” hypothesis in Down syndrome. J Neural Transm. Suppl 57 293-303.
11. CJ Epstein (1988) Specificity versus nonspecificity in the pathogenesis of aneuploid phenotypes. Am J Med Genet 29 161-165.
12. B Hall (1965) Delayed ontogenesis in human trisomy syndromes. Hereditas 52 334-344.
13. BL Shapiro (1994) The environmental basis of the Down syndrome phenotype. Dev Med Child Neurol 36 84-90.
14. BW Brooksbank and R Balazs (1984) Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. Brain Res 318 37-44.
15. KG Anneren and CJ Epstein (1987) Lipid peroxidation and superoxide dismutase-1 and glutathione peroxidase activities in trisomy 16 fetal mice and human trisomy 21 fibroblasts. Pediatr Res 21 88-92.
16. N Lemieux, B Malfoy and GL Forrest (1993) Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cell. Genomics 15 169-172.
17. C Pallister, SS Jung, I Shaw, J Nalbantoglu, S Gauthier and NR Cashman (1997) Lymphocyte content of amyloid precursor protein is increased in Down's syndrome and aging. Neurobiol Aging 18 97-103.
18. JJ Fuentes, L Genesca, TJ Kingsbury, KW Cunningham, M Perez-Riba, X Estivill and L.S. de la Luna S (2000) DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum Mol Genet 9 1681-1690.
19. I Ceballos, A Nicole, P Briand, G Grimber, A Delacourte, S Flament, JL Blouin, M Thevenin, P Kamoun and PM Sinet (1991) Expression of human Cu-Zn superoxide dismutase gene in transgenic mice: model for gene dosage effect in Down syndrome. Free Radic Res Commun 12–13 581-589.
20. SH Sumarsono, TJ Wilson, MJ Tymms, DJ Venter, CM Corrick, R Kola, MH Lahoud, TS Papas and A Seth (1996) Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice. Nature 379 534-537.
21. L Stefani, J Galt, A Palmer, N Affara, M Ferguson-Smith and NC Nevin (1988) Expression of chromosome 21 specific sequences in normal and Down's syndrome tissues. Nucleic Acids Res 16 2885-2896.
22. S Greber-Platzer, D Schatzmann-Turhani, G Wollenek and G Lubec (1999) Evidence against the current hypothesis of “gene dosage effects” of trisomy 21: ets-2, encoded on chromosome 21 is not overexpressed in hearts of patients. Biochem Biophys Res Commun 254 395-399.
23. MS Cheon, KS Shim, SH Kim, A Hara and G Lubec (2003) Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part IV). Amino Acids 25 41-47.
24. MS Cheon, SH Kim, V Ovod, J.N. Kopitar Jerala N, JI Morgan, Y Hatefi, T Ijuin, T Takenawa and G Lubec (2003) Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part III). Amino Acids 24 127-134.
25. RC Iannello, PJ Crack, H.J.B. de Haan JB and I Kola (1999) Oxidative stress and neural dysfunction in Down syndrome. J Neural Transm. Suppl 57 257-267.
26. DA O'Leary, MA Pritchard, D Xu, I Kola, PJ Hertzog and S Ristevski (2004) Tissue-specific overexpression of the HSA21 gene GABPalpha: implications for DS. Biochim Biophys Acta 1739 81-87.
27. JJ Fuentes, MA Pritchard, AM Planas, A Bosch, I Ferrer and X Estivill (1995) A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Hum Mol Genet 4 1935-1944.
28. C Pucharcos, JJ Fuentes, C Casas, L.S. de la Luna S, S Alcantara, ML Arbones, E Soriano, X Estivill and M Pritchard (1999) Alu-splice cloning of human Intersectin (ITSN), a putative multivalent binding protein expressed in proliferating and differentiating neurons and overexpresse. Eur J Hum Genet 7 704-712.
29. J Guimera, C Casas, X Estivill and M Pritchard (1999) Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. Genomics 57 407-418.
30. L Mittaz, DL Russell, T Wilson, M Brasted, J Tkalcevic, LA Salamonsen, PJ Hertzog and MA Pritchard (2004) Adamts-1 is essential for the development and function of the urogenital system. Biol Reprod 70 1096-1105.
31. YH Tan, J Tischfield and FH Ruddle (1973) The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21. J Exp Med 137 317-330.
32. H.J.B. de Haan JB, EJ Wolvetang, F Cristiano, R Iannello, C Bladier, MJ Kelner and I Kola (1997) Reactive oxygen species and their contribution to pathology in Down syndrome. Adv Pharmacol 38 379-402.
33. H.J.B. de Haan JB, B Susil, M Pritchard and I Kola (2003) An altered antioxidant balance occurs in Down syndrome fetal organs: implications for the “gene dosage effect” hypothesis. J Neural Transm. Suppl. 67-83.
34. PM Sinet, F Lavelle, AM Michelson and H Jerome (1975) Superoxide dismutase activities of blood platelets in trisomy 21. Biochem Biophys Res Commun 67 904-909.
35. H Frischer, LK Chu, T Ahmad, P Justice and GF Smith (1981) Superoxide dismutase and glutathione peroxidase abnormalities in erythrocytes and lymphoid cells in Down syndrome. Prog Clin Biol Res 55 269-289.
36. MC Pastor, C Sierra, M Dolade, E Navarro, N Brandi, E Cabre, A Mira and A Seres (1998) Antioxidant enzymes and fatty acid status in erythrocytes of Down's syndrome patients. Clin Chem 44 924-929.
37. T Gulesserian, R Seidl, R Hardmeier, N Cairns and G Lubec (2001) Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med 49 41-46.
38. T Gulesserian, E Engidawork, M Fountoulakis and G Lubec (2001) Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J Neural Transm. Suppl. 71-84.
39. L.T.R. de La Torre R, A Casado, E Lopez-Fernandez, D Carrascosa, V Ramirez and J Saez (2001) Overexpression of copper-zinc superoxide dismutase in trisomy 21. Experientia 52 871-873.
40. RL Neve, EA Finch and LR Dawes (1988) Expression of the Alzheimer amyloid precursor gene transcripts in the human brain. Neuron 1 669-677.
41. DM Holtzman, RM Bayney, YW Li, H Khosrovi, CN Berger, CJ Epstein and WC Mobley (1992) Dysregulation of gene expression in mouse trisomy 16, an animal model of Down syndrome. EMBO J 11 619-627.
42. MS Cheon, M Bajo, SH Kim, JO Claudio, AK Stewart, D Patterson, WD Kruger, H Kondoh and G Lubec (2003) Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part II). Amino Acids 24 119-125.
43. I Fridovich (1978) Superoxide dismutases: defence against endogenous superoxide radical. Ciba Found Symp. 77-93.
44. JA Imlay and S Linn (1988) DNA damage and oxygen radical toxicity. Science 240 1302-1309.
45. KJ Davies (1987) Protein damage and degradation by oxygen radicals. I. General aspects. J Biol Chem 262 9895-9901.
46. H Sies and G.H. de Groot H (1992) Role of reactive oxygen species in cell toxicity. Toxicol Lett 64-65 547-551.
47. F Cand and J Verdetti (1989) Superoxide dismutase, glutathione peroxidase, catalase, and lipid peroxidation in the major organs of the aging rats. Free Radic Biol Med 7 59-63.
48. B Chance, H Sies and A Boveris (1979) Hydroperoxide metabolism in mammalian organs. Physiol Rev 59 527-605.
49. J Neve, PM Sinet, L Molle and A Nicole (1983) Selenium, zinc and copper in Down's syndrome (trisomy 21): blood levels and relations with glutathione peroxidase and superoxide dismutase. Clin Chim Acta 133 209-214.
50. G Ermak, CD Harris and KJ Davies (2002) The DSCR1 (Adapt78) isoform 1 protein calcipressin 1 inhibits calcineurin and protects against acute calcium-mediated stress damage, including transient oxida. FASEB J 16 814-824.
51. G Ermak, TE Morgan and KJ Davies (2001) Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease. J Biol Chem 276 38787-38794.
52. J Busciglio, A Pelsman, C Wong, G Pigino, M Yuan, H Mori and BA Yankner (2002) Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33 677-688.
53. KT Chang and KT Min (2005) Drosophila melanogaster homolog of Down syndrome critical region 1 is critical for mitochondrial function. Nat Neurosci 8 1577-1585.
54. I Kola and PJ Hertzog (1997) Animal models in the study of the biological function of genes on human chromosome 21 and their role in the pathophysiology of Down syndrome. Hum Mol Genet 6 1713-1727.
55. I Tayarani, I Cloez, M Clement and JM Bourre (1989) Antioxidant enzymes and related trace elements in aging brain capillaries and choroid plexus. J Neurochem 53 817-824.
56. G Benzi, O Pastoris and RF Villa (1988) Changes induced by aging and drug treatment on cerebral enzymatic antioxidant system. Neurochem Res 13 467-478.
57. A Sahoo and GB Chainy (1997) Alterations in the activities of cerebral antioxidant enzymes of rat are related to aging. Int J Dev Neurosci 15 939-948.
58. DH Boehme, R Kosecki, S Carson, F Stern and N Marks (1977) Lipoperoxidation in human and rat brain tissue: developmental and regional studies. Brain Res 136 11-21.
59. H.J.B. de Haan JB, JD Newman and I Kola (1992) Cu/Zn superoxide dismutase mRNA and enzyme activity, and susceptibility to lipid peroxidation, increases with aging in murine brains. Brain Res Mol Brain Res 13 179-187.
60. F Cristiano, H.J.B. de Haan JB, RC Iannello and I Kola (1995) Changes in the levels of enzymes which modulate the antioxidant balance occur during aging and correlate with cellular damage. Mech Aging Dev 80 93-105.
61. H.J.B. de Haan JB, F Cristiano, R Iannello, C Bladier, MJ Kelner and I Kola (1996) Elevation in the ratio of Cu/Zn-superoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by. Hum Mol Genet 5 283-292.
62. H.J.B. de Haan JB, C Bladier, M Lotfi-Miri, J Taylor, P Hutchinson, PJ Crack, P Hertzog and I Kola (2004) Fibroblasts derived from Gpx1 knockout mice display senescent-like features and are susceptible to H2O2-mediated cell death. Free Radic Biol Med 36 53-64.
63. R Dringen (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 62 649-671.
64. PM Doraiswamy and AE Finefrock (2004) Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol 3 431-434.
65. B Halliwell (1999) Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 31 261-272.
66. R Levy, S Glozman, D Milman, C Seruty, Z Hagay, E Yavin and Y Groner (2002) Ischemic reperfusion brain injury in fetal transgenic mice with elevated levels of copper-zinc superoxide dismutase. J Perinat Med 30 158-165.
67. R Yarom, D Sapoznikov, Y Havivi, KB Avraham, M Schickler and Y Groner (1988) Premature aging changes in neuromuscular junctions of transgenic mice with an extra human CuZnSOD gene: a model for tongue pathology in Down's syndrome. J Neurol Sci 88 41-53.
68. KB Avraham, M Schickler, D Sapoznikov, R Yarom and Y Groner (1988) Down's syndrome: abnormal neuromuscular junction in tongue of transgenic mice with elevated levels of human Cu/Zn-superoxide dismutase. Cell 54 823-829.
69. M Peled-Kamar, J Lotem, I Wirguin, L Weiner, A Hermalin and Y Groner (1997) Oxidative stress mediates impairment of muscle function in transgenic mice with elevated level of wild-type Cu/Zn superoxide dismutase. Proc Natl Acad Sci USA 94 3883-3887.
70. O Bar-Peled, E Korkotian, M Segal and Y Groner (1996) Constitutive overexpression of Cu/Zn superoxide dismutase exacerbates kainic acid-induced apoptosis of transgenic-Cu/Zn superoxide dismutase neurons. Proc Natl Acad Sci USA 93 8530-8535.
71. Y Levkovitz, E Avignone, Y Groner and M Segal (1999) Upregulation of GABA neurotransmission suppresses hippocampal excitability and prevents long-term potentiation in transgenic superoxide dismutase-overexpressi. J Neurosci 19 10977-10984.
72. E Gahtan, JM Auerbach, Y Groner and M Segal (1998) Reversible impairment of long-term potentiation in transgenic Cu/Zn-SOD mice. Eur J Neurosci 10 538-544.
73. O Elroy-Stein and Y Groner (1988) Impaired neurotransmitter uptake in PC12 cells overexpressing human Cu/Zn-superoxide dismutase — implication for gene dosage effects in Down syndrome. Cell 52 259-267.
74. H.J.B. de Haan JB, C Bladier, P Griffiths, M Kelner, RD O'Shea, NS Cheung, RT Bronson, MJ Silvestro, S Wild, SS Zheng, PM Beart, PJ Hertzog and I Kola (1998) Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agents. J Biol Chem 273 22528-22536.
75. JM Taylor, U Ali, RC Iannello, P Hertzog and PJ Crack (2005) Diminished Akt phosphorylation in neurons lacking glutathione peroxidase-1 (Gpx1) leads to increased susceptibility to oxidative stress-induced cell death. J Neurochem 92 283-293.
76. PJ Crack, JM Taylor, NJ Flentjar, H.J. de Haan J, P Hertzog, RC Iannello and I Kola (2001) Increased infarct size and exacerbated apoptosis in the glutathione peroxidase-1 (Gpx-1) knockout mouse brain in response to ischemia/reperfusion injury. J Neurochem 78 1389-1399.
77. NJ Flentjar, PJ Crack, R Boyd, M Malin, H.J.B. de Haan JB, P Hertzog, I Kola and R Iannello (2002) Mice lacking glutathione peroxidase-1 activity show increased TUNEL staining and an accelerated inflammatory response in brain following a cold-induced injury. Exp Neurol 177 9-20.
78. R Yao and GM Cooper (1995) Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267 2003-2006.
79. H Dudek, SR Datta, TF Franke, MJ Birnbaum, R Yao, GM Cooper, RA Segal, DR Kaplan and ME Greenberg (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275 661-665.
80. L Hertz, R Dringen, A Schousboe and SR Robinson (1999) Astrocytes: glutamate producers for neurons. J Neurosci Res 57 417-428.
81. T Knorpp, SR Robinson, PJ Crack and R Dringen (2006) Glutathione peroxidase-1 contributes to the protection of glutamine synthetase in astrocytes during oxidative stress. J Neural Transm 113 1145-1155.
82. E Sanij, T Hatzistavrou, P Hertzog, I Kola and EJ Wolvetang (2001) Ets-2 is induced by oxidative stress and sensitizes cells to H2O2-induced apoptosis: implications for Down's syndrome. Biochem Biophys Res Commun 287 1003-1008.
83. EJ Wolvetang, OM Bradfield, T Hatzistavrou, PJ Crack, J Busciglio, I Kola and PJ Hertzog (2003) Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis. Neurobiol Dis 14 349-356.
84. EJ Wolvetang, TJ Wilson, E Sanij, J Busciglio, T Hatzistavrou, A Seth, PJ Hertzog and I Kola (2003) ETS2 over-expression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway. Hum Mol Genet 12 247-255.
85. RW Keefover (1996) The clinical epidemiology of Alzheimer's disease. Neurol Clin 14 337-351.
86. FP Zemlan, OJ Thienhaus and HB Bosmann (1989) Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. Brain Res 476 160-162.
87. K Beyreuther, P Pollwein, G Multhaup, U Monning, G Konig, T Dyrks, W Schubert and CL Masters (1993) Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome. Ann NY Acad Sci 695 91-102.
88. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20 154-159.
89. ND Mehta, LM Refolo, C Eckman, S Sanders, D Yager, J Perez-Tur, S Younkin, K Duff, J Hardy and M Hutton (1998) Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 43 256-258.
90. MP Mattson (1997) Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77 1081-1132.
91. JK Teller, C Russo, LM DeBusk, G Angelini, D Zaccheo, F Dagna-Bricarelli, P Scartezzini, S Bertolini, DM Mann, M Tabaton and P Gambetti (1996) Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2 93-95.
92. AL Friedlich and LL Butcher (1994) Involvement of free oxygen radicals in beta-amyloidosis: an hypothesis. Neurobiol Aging 15 443-455.
93. MF Beal (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1366 211-223.
94. K Hensley, JM Carney, MP Mattson, M Aksenova, M Harris, JF Wu, RA Floyd and DA Butterfield (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 91 3270-3274.
95. C Behl, JB Davis, R Lesley and D Schubert (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77 817-827.
96. MP Mattson, B Cheng, AR Culwell, FS Esch, I Lieberburg and RE Rydel (1993) Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10 243-254.
97. C Behl, JB Davis, FG Klier and D Schubert (1994) Amyloid beta peptide induces necrosis rather than apoptosis. Brain Res 645 253-264.
98. C Behl (1997) Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res 290 471-480.
99. SD Yan, X Chen, J Fu, M Chen, H Zhu, A Roher, T Slattery, L Zhao, M Nagashima, J Morser, A Migheli, P Nawroth, D Stern and AM Schmidt (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 685-691.
100. G Multhaup, T Ruppert, A Schlicksupp, L Hesse, D Beher, CL Masters and K Beyreuther (1997) Reactive oxygen species and Alzheimer's disease. Biochem Pharmacol 54 533-539.
101. SD Yan, SF Yan, X Chen, J Fu, M Chen, P Kuppusamy, MA Smith, G Perry, GC Godman, P Nawroth, JL Zweier and D Stern (1995) Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptid. Nat Med 1 693-699.
102. Y Sagara, R Dargusch, FG Klier, D Schubert and C Behl (1996) Increased antioxidant enzyme activity in amyloid beta protein-resistant cells. J Neurosci 16 497-505.
103. PJ Crack, K Cimdins, U Ali, PJ Hertzog and RC Iannello (2006) Lack of glutathione peroxidase-1 exacerbates Abeta-mediated neurotoxicity in cortical neurons. J Neural Transm 113 645-657.
104. M Barkats, S Millecamps, P Abrioux, MC Geoffroy and J Mallet (2000) Overexpression of glutathione peroxidase increases the resistance of neuronal cells to Abeta-mediated neurotoxicity. J Neurochem 75 1438-1446.
105. H Shinall, ES Song and LB Hersh (2005) Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry 44 15345-15350.
106. K Maruyama, K Terakado, M Usami and K Yoshikawa (1990) Formation of amyloid-like fibrils in COS cells overexpressing part of the Alzheimer amyloid protein precursor. Nature 347 566-569.
107. XD Liu and DJ Thiele (1996) Oxidative stress induced heat shock factor phosphorylation and HSF-dependent activation of yeast metallothionein gene transcription. Genes Dev 10 592-603.
108. EW Wolvetang, OM Bradfield, M Tymms, S Zavarsek, T Hatzistavrou, I Kola and PJ Hertzog (2003) The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome. Biochim Biophys Acta 1628 105-110.
109. C Harris-Cerruti, A Kamsler, B Kaplan, B Lamb, M Segal and Y Groner (2004) Functional and morphological alterations in compound transgenic mice overexpressing Cu/Zn superoxide dismutase and amyloid precursor protein [correction]. Eur J Neurosci 19 1174-1190.
110. H Hara, H Kato and K Kogure (1990) Protective effect of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus. Brain Res 510 335-338.
111. C Behl, J Davis, GM Cole and D Schubert (1992) Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun 186 944-950.
112. M Sano, C Ernesto, RG Thomas, MR Klauber, K Schafer, M Grundman, P Woodbury, J Growdon, CW Cotman, E Pfeiffer, LS Schneider and LJ Thal (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336 1216-1222.
113. C Ani, S Grantham-McGregor and D Muller (2000) Nutritional supplementation in Down syndrome: theoretical considerations and current status. Dev Med Child Neurol 42 207-213.
114. E Antila, UR Nordberg, EL Syvaoja and T Westermarck (1990) Selenium therapy in Down syndrome (DS): a theory and a clinical trial. Adv Exp Med Biol 264 183-186.
115. KE Wisniewski (1990) Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am J Med Genet. Suppl 7 274-281.